Limits...
The effects of wenxin keli on left ventricular ejection fraction and brain natriuretic Peptide in patients with heart failure: a meta-analysis of randomized controlled trials.

Chen Y, Xiong X, Wang C, Wang C, Zhang Y, Zhang X, Gao Y, Xing Y, Li J, Wang J, Liu X, Xing Y - Evid Based Complement Alternat Med (2014)

Bottom Line: Objective.Methods.The results of the meta-analysis showed that WXKL, either alone or in combination with Western medicine, was more effective in LVEF and BNP, compared with no medicine or Western medicine alone, in patients with HF or HF complicated by other diseases.

View Article: PubMed Central - PubMed

Affiliation: Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China ; Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing 100053, China.

ABSTRACT
Objective. To evaluate the beneficial and adverse effects of Wenxin Keli (WXKL), either alone or in combination with Western medicine, on the left ventricular ejection fraction (LVEF) and plasma brain natriuretic peptide (BNP) in the treatment of heart failure (HF). Methods. Seven major electronic databases were searched to retrieve potential randomized controlled trials (RCTs) designed to evaluate the clinical effectiveness of WXKL, either alone or in combination with Western medicine, for HF, with the LVEF or BNP after eight weeks of treatment as main outcome measures. The methodological quality of the included studies was assessed using criteria from the Cochrane Handbook for Systematic Review of Interventions, Version 5.1.0, and analyzed using RevMan 5.1.0 software. Results. Eleven RCTs of WXKL were included. The methodological quality of the trials was generally evaluated as low. The risk of bias was high. The results of the meta-analysis showed that WXKL, either alone or in combination with Western medicine, was more effective in LVEF and BNP, compared with no medicine or Western medicine alone, in patients with HF or HF complicated by other diseases. Five of the trials reported adverse events, while the others did not mention them, indicating that the safety of WXKL remains uncertain. Conclusions. WXKL, either alone or in combination with Western medicine, appears to be more effective in improving the LVEF and BNP in patients with HF and HF complications.

No MeSH data available.


Related in: MedlinePlus

Flow chart of articles selection process.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4020470&req=5

fig1: Flow chart of articles selection process.

Mentions: After the primary search of the seven databases both in Chinese and English, 599 articles were retrieved: Cochrane Library (n = 0), PubMed (n = 3), Embase (n = 4), CNKI (n = 159), VIP (n = 120), CBMdisc (n = 156), and Wanfang (n = 157). The majority of these trials were excluded because some papers were found in more than one database and some included irrelevant titles and abstracts. Only 149 studies were retrieved. Following a review of the titles and abstracts, several studies were excluded, and only 126 studies remained. Five trials were excluded because of duplicated publications. Thirteen trials were excluded for being animal studies, and five trials were excluded for being nonclinical trials, including case reports and traditional reviews. One hundred and fifteen out of the remaining 126 articles were excluded based on the inclusion criteria, leaving eleven RCTs to be reviewed [8–18]. The screening process is summarized in a flow chart (Figure 1). All of the trials were conducted in China and published in Chinese. The characteristics of the eleven RCTs are summarized in Table 1.


The effects of wenxin keli on left ventricular ejection fraction and brain natriuretic Peptide in patients with heart failure: a meta-analysis of randomized controlled trials.

Chen Y, Xiong X, Wang C, Wang C, Zhang Y, Zhang X, Gao Y, Xing Y, Li J, Wang J, Liu X, Xing Y - Evid Based Complement Alternat Med (2014)

Flow chart of articles selection process.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4020470&req=5

fig1: Flow chart of articles selection process.
Mentions: After the primary search of the seven databases both in Chinese and English, 599 articles were retrieved: Cochrane Library (n = 0), PubMed (n = 3), Embase (n = 4), CNKI (n = 159), VIP (n = 120), CBMdisc (n = 156), and Wanfang (n = 157). The majority of these trials were excluded because some papers were found in more than one database and some included irrelevant titles and abstracts. Only 149 studies were retrieved. Following a review of the titles and abstracts, several studies were excluded, and only 126 studies remained. Five trials were excluded because of duplicated publications. Thirteen trials were excluded for being animal studies, and five trials were excluded for being nonclinical trials, including case reports and traditional reviews. One hundred and fifteen out of the remaining 126 articles were excluded based on the inclusion criteria, leaving eleven RCTs to be reviewed [8–18]. The screening process is summarized in a flow chart (Figure 1). All of the trials were conducted in China and published in Chinese. The characteristics of the eleven RCTs are summarized in Table 1.

Bottom Line: Objective.Methods.The results of the meta-analysis showed that WXKL, either alone or in combination with Western medicine, was more effective in LVEF and BNP, compared with no medicine or Western medicine alone, in patients with HF or HF complicated by other diseases.

View Article: PubMed Central - PubMed

Affiliation: Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China ; Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing 100053, China.

ABSTRACT
Objective. To evaluate the beneficial and adverse effects of Wenxin Keli (WXKL), either alone or in combination with Western medicine, on the left ventricular ejection fraction (LVEF) and plasma brain natriuretic peptide (BNP) in the treatment of heart failure (HF). Methods. Seven major electronic databases were searched to retrieve potential randomized controlled trials (RCTs) designed to evaluate the clinical effectiveness of WXKL, either alone or in combination with Western medicine, for HF, with the LVEF or BNP after eight weeks of treatment as main outcome measures. The methodological quality of the included studies was assessed using criteria from the Cochrane Handbook for Systematic Review of Interventions, Version 5.1.0, and analyzed using RevMan 5.1.0 software. Results. Eleven RCTs of WXKL were included. The methodological quality of the trials was generally evaluated as low. The risk of bias was high. The results of the meta-analysis showed that WXKL, either alone or in combination with Western medicine, was more effective in LVEF and BNP, compared with no medicine or Western medicine alone, in patients with HF or HF complicated by other diseases. Five of the trials reported adverse events, while the others did not mention them, indicating that the safety of WXKL remains uncertain. Conclusions. WXKL, either alone or in combination with Western medicine, appears to be more effective in improving the LVEF and BNP in patients with HF and HF complications.

No MeSH data available.


Related in: MedlinePlus